Peters A M, Saverymuttu S H, Wonke B, Lewis S M, Lavender J P
Br J Haematol. 1984 Aug;57(4):637-49.
The kinetics of platelets labelled with 111In have been studied in a series of 175 subjects including 18 normal volunteers, and 12 patients with idiopathic thrombocytopenic purpura (ITP), but excluding patients in whom there was scintigraphic evidence of intravascular platelet consumption. From analysis of the kinetics, the following parameters were calculated: splenic blood flow (SBF), intrasplenic platelet transit time (t-), splenic platelet pool capacity (expressed as a percentage of the total circulating platelet population), the fraction of the dose of labelled platelets ultimately destroyed in the spleen and the mean platelet life span (MPLS). SBF increased with increasing spleen size up to values of 25% total blood volume (TBV) per min. Some patients with immune complex related diseases were identified with elevated SBF (up to 24% TBV min-1) but without significant splenomegaly. Patients with cardiac decompensation had reduced SBF relative to spleen size. t- showed no relationship with spleen size. It tended to fall in patients who had high SBF relative to spleen size and to rise in those with low SBF relative to spleen size; i.e. it was inversely related to splenic perfusion (flow per unit tissue volume). The splenic platelet pool capacity is dependent on platelet input (SBF) and splenic platelet clearance (reciprocal of t-), and showed a close relationship with spleen size. When all subjects except those with ITP were considered, splenic platelet destruction showed a good correlation (r = 0.70, n = 42, P less than 0.001) with the splenic platelet pooling capacity. The ratio of the fraction of platelets destroyed in the spleen to the fraction pooling there, the D/P ratio, was approximately unity and did not appear to vary with MPLS, spleen size or the patient's condition, except in ITP where it varied between about 0.5 and 2. This variation in ITP was thought to be the result of an immune mediated re-direction of reticulo-endothelial platelet destruction. It is suggested that the D/P ratio, rather than the absolute quantity of 111In labelled platelets destroyed in the spleen, may be a more useful predictor of response to splenectomy since it takes into account the observed, appropriate, tendency for the spleen to destroy platelets in proportion to its platelet pooling capacity.
对175名受试者(包括18名正常志愿者和12名特发性血小板减少性紫癜(ITP)患者)进行了研究,观察了用铟-111标记的血小板的动力学情况,但排除了闪烁显像有血管内血小板消耗证据的患者。通过动力学分析,计算了以下参数:脾血流量(SBF)、脾内血小板通过时间(t-)、脾血小板池容量(以循环血小板总数的百分比表示)、标记血小板剂量最终在脾脏中被破坏的比例以及平均血小板寿命(MPLS)。SBF随着脾脏大小增加而增加,最高可达每分钟总血容量(TBV)的25%。一些免疫复合物相关疾病患者的SBF升高(最高可达24% TBV/min),但无明显脾肿大。心脏代偿失调患者的SBF相对于脾脏大小降低。t-与脾脏大小无关。相对于脾脏大小,SBF高的患者t-往往降低,SBF低的患者t-往往升高;即它与脾灌注(单位组织体积的血流量)呈负相关。脾血小板池容量取决于血小板输入(SBF)和脾血小板清除率(t-的倒数),并与脾脏大小密切相关。当考虑除ITP患者外的所有受试者时,脾血小板破坏与脾血小板池容量显示出良好的相关性(r = 0.70,n = 42,P < 0.001)。在脾脏中被破坏的血小板比例与在脾脏中聚集的血小板比例之比,即D/P比,约为1,除ITP患者外,似乎不随MPLS、脾脏大小或患者病情而变化,ITP患者的D/P比在约0.5至2之间变化。ITP中的这种变化被认为是免疫介导的网状内皮系统对血小板破坏重新定向的结果。有人提出,D/P比,而不是脾脏中被破坏的铟-111标记血小板的绝对数量,可能是脾切除反应更有用的预测指标,因为它考虑到了观察到的脾脏按其血小板池容量比例破坏血小板的适当倾向。